188 pts with 307 pt years (PY). Rates/100PY of AEs and serious AEs (SAEs) were 406.5 and 11.1, respectively; infections were the most common AE (151.4) and SAE (5.2). ALT and AST elevation !3Â upper limit of normal occurred in 6.4% and 2.7% of pts, respectively. Grade 3 neutropenia and grade 2/3/4 thrombocytopenia occurred in 5.9% and 1.6% of pts, respectively. LDL cholesterol !110 mg/dl occurred in 16.2% of pts. Conclusion: Efficacy of TCZ was maintained through 2 years of treatment in pts with pcJIA, with no change in safety profile from that reported previously. Method: Nucleic Acid Programmable Protein Array (NAPPA) enables the production of multiple proteins from DNA templates which are immobilized on a solid phase. These can then be probed for the presence of autoantibodies in patient's serum. NAPPA slides with 2200 genes were produced. PubMed search identified $60 genes associated with uveitis pathology and $30 genes associated with arthritis development. The remaining $2100 genes were randomly identified from a $12 000 human gene collection (http://dnasu.asu.edu) (Fig. 1) . The arrays were then probed using plasma from JIA patients with (n ¼ 20) and without uveitis (n ¼ 20) and from healthy age and sex matched controls (n ¼ 20). Results: Quantitative reproducibility of NAPPAs was demonstrated with > 0.95 intra-array and inter-array correlations. Differences in the levels of potential autoantibodies were revealed between JIA patients with and without uveitis. Patients were segregated into two clinical subtypes with distinct antibody signatures by unsupervised hierarchical cluster analysis. Conclusion: The NAPPA platform has the potential to identify novel autoantibodies that robustly forecast the development of uveitis in children with Juvenile idiopathic arthritis. This predictive tool could enable the development of a more appropriate, effective and efficient clinical management algorithm. Disclosure statement: The authors have declared no conflicts of interest.
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